Dr. Reddy’s API plant completes U.S. FDA inspection in Srikakulam facility

Dr Reddy's Laboratories Ltd. said in the regulatory filing on Wednesday that the US FDA (Food and Drug Administration) has successfully completed both the pre-approval inspection and a routine inspection of good manufacturing practices at the API manufacturing facility in Srikakulam, Andhra Pradesh, with no observations.

The facility for active pharmaceutical ingredients (APIs) was examined between July 10 and July 19, 2023. 

According to the company's filing with the exchange, it closed with no observations and was classified as No Action Indicated (NAI).

Reacting to this news, the share price of the company gained by Rs 148.6 or 2.8% at Rs 5,370.2 apiece on BSE, surpassing an earlier 52-week high of Rs 5,272.4 apiece hit on July 7.

Source: Media Reports

Top stories
Budget

Impact of Budget on Healthcare Sector

2 mins read . 24 Jul 2024 . 05:10 AM

Budget

Impact of Budget on Stock Market

4 mins read . 24 Jul 2024 . 05:06 AM

Budget

Impact of Budget on Common Man

9 mins read . 23 Jul 2024 . 12:22 PM

Related Blogs
blog-logo

Share Market

blog-logo

8 mins read . 19 Jul 2024

Stock Market Trading Time in India

  • 38 people read
blog-logo

Share Market

blog-logo

11 mins read . 19 Jul 2024

How To Trade in T2T Stocks

  • 38 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions